



## PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item: Perinatal and Neurodevelopmental Outcomes of Fetal Isolated Ventriculomegaly. A systematic review and meta-analysis	Location where item is reported
<b>TITLE</b>			
Title	1	Identify the report as a systematic review.	Line 3
<b>ABSTRACT</b>			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Line 40-68
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Line 108-110
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Line 41-44
<b>METHODS</b>			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Line 139-156
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Line 123
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Line 120-131
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Line 167-171
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Line 182-195
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Line 187-193
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Line 151-156, 475-482
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Line 197-212
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Line 212-233
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Line 236-242
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Line 244-284
	13c	Describe any methods used to tabulate or visually display the results of individual studies and syntheses.	Line 221-233
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Line 222-226
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Line 229-



# PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item: Perinatal and Neurodevelopmental Outcomes of Fetal Isolated Ventriculomegaly. A systematic review and meta-analysis	Location where item is reported
			223
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Line 228-233
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	Line 286-296
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Line 202-212
<b>RESULTS</b>			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Line 234-242
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Line 242
Study characteristics	17	Cite each included study and present its characteristics.	Line 245
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Line 286
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Line 350-362
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Line 330-349
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Line 314-362
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Line 330-349
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Line 350-359
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Line 277-278
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Line 336-349
<b>DISCUSSION</b>			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Line 381 - 407
	23b	Discuss any limitations of the evidence included in the review.	Line 425-427
	23c	Discuss any limitations of the review processes used.	Line 417-424
	23d	Discuss implications of the results for practice, policy, and future research.	line 440-469



## PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item: Perinatal and Neurodevelopmental Outcomes of Fetal Isolated Ventriculomegaly. A systematic review and meta-analysis	Location where item is reported
<b>OTHER INFORMATION</b>			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Line 121
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Line 121
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	Line 121
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Line 476-482
Competing interests	26	Declare any competing interests of review authors.	Line 471
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Line 121

Article information: <https://dx.doi.org/10.21037/tp-23-548>

\*As the checklist was provided upon initial submission, the line number reported may be changed due to copyediting and may not be referable in the published version.